S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
66,000% upside on tiny biotech? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
66,000% upside on tiny biotech? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
66,000% upside on tiny biotech? (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
66,000% upside on tiny biotech? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
66,000% upside on tiny biotech? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
66,000% upside on tiny biotech? (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
66,000% upside on tiny biotech? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
66,000% upside on tiny biotech? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
66,000% upside on tiny biotech? (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
S&P 500   4,299.70
DOW   33,666.34
QQQ   358.01
Can Undervalued Healthcare Stocks Add Yield To Your Portfolio?
66,000% upside on tiny biotech? (Ad)
Stock market today: European shares gain and Asian shares are mixed, with Chinese markets on holiday
Nursing Home REITs: The Surprise Heroes of High Yield Investing
66,000% upside on tiny biotech? (Ad)
Energy Stocks Shine as High Oil Prices Boost Dividend Yields
Billionaire Ryan Cohen takes over as CEO at GameStop, adding to chairman role
66,000% upside on tiny biotech? (Ad)
Liverpool owner FSG announces minority investment by New York equity firm
3 Reasons Micron is a Buy on Market Weakness
NASDAQ:DTIL

Precision BioSciences (DTIL) Stock Forecast, Price & News

$0.36
-0.01 (-2.73%)
(As of 09/28/2023 ET)
Compare
Today's Range
$0.35
$0.37
50-Day Range
$0.36
$0.64
52-Week Range
$0.35
$1.70
Volume
354,584 shs
Average Volume
750,001 shs
Market Capitalization
$40.98 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Precision BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
742.5% Upside
$3.00 Price Target
Short Interest
Healthy
1.75% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.99
Upright™ Environmental Score
News Sentiment
0.54mentions of Precision BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.77) to ($0.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

269th out of 969 stocks

Biological Products, Except Diagnostic Industry

43rd out of 161 stocks


DTIL stock logo

About Precision BioSciences (NASDAQ:DTIL) Stock

Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

DTIL Price History

DTIL Stock News Headlines

Precision BioSciences' (DTIL) Buy Rating Reaffirmed at HC Wainwright
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
What 4 Analyst Ratings Have To Say About Precision BioSciences
This Stock Could Go Up 66% or More.
Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023.  Click here to get his latest buy.  More here.
BTIG Sticks to Their Buy Rating for Precision BioSciences (DTIL)
The Latest Analyst Ratings for Precision BioSciences
See More Headlines
Receive DTIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Precision BioSciences and its competitors with MarketBeat's FREE daily newsletter.

DTIL Company Calendar

Last Earnings
8/04/2023
Today
9/29/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DTIL
Fax
N/A
Employees
192
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+742.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-111,640,000.00
Net Margins
-192.10%
Pretax Margin
-192.10%

Debt

Sales & Book Value

Annual Sales
$25.10 million
Book Value
$0.54 per share

Miscellaneous

Free Float
105,290,000
Market Cap
$40.98 million
Optionable
Not Optionable
Beta
1.31
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Michael Amoroso (Age 45)
    Pres, CEO & Director
    Comp: $979.04k
  • Mr. John Alexander Kelly R.Ph. (Age 56)
    Chief Financial Officer
    Comp: $623.58k
  • Mr. Dario Scimeca (Age 47)
    Gen. Counsel & Sec.
    Comp: $576.43k
  • Dr. Derek Jantz Ph.D. (Age 47)
    Co-Founder & Chief Science Advisor
  • Dr. Jefferson J. Smith Ph.D. (Age 50)
    Co-Founder & Chief Research Officer
  • Mr. Shane Barton (Age 52)
    VP, Corp. Controller & Principal Accounting Officer
  • Mei Burris
    Director of Investor Relations & Fin.
  • Mr. Bruce Stevens
    VP of Quality & Compliance
  • Maurissa Messier
    Sr. Director of Corp. Communications
  • Ms. Juli Blanche
    Chief People Officer













DTIL Stock - Frequently Asked Questions

Should I buy or sell Precision BioSciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Precision BioSciences in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DTIL shares.
View DTIL analyst ratings
or view top-rated stocks.

What is Precision BioSciences' stock price forecast for 2023?

3 brokerages have issued twelve-month target prices for Precision BioSciences' shares. Their DTIL share price forecasts range from $2.00 to $4.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 742.5% from the stock's current price.
View analysts price targets for DTIL
or view top-rated stocks among Wall Street analysts.

How have DTIL shares performed in 2023?

Precision BioSciences' stock was trading at $1.19 at the beginning of 2023. Since then, DTIL stock has decreased by 70.1% and is now trading at $0.3561.
View the best growth stocks for 2023 here
.

When is Precision BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our DTIL earnings forecast
.

How were Precision BioSciences' earnings last quarter?

Precision BioSciences, Inc. (NASDAQ:DTIL) released its quarterly earnings results on Friday, August, 4th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.23) by $0.13. The firm had revenue of $19.79 million for the quarter, compared to analyst estimates of $6.58 million. Precision BioSciences had a negative trailing twelve-month return on equity of 163.24% and a negative net margin of 192.10%.

What ETF holds Precision BioSciences' stock ?

Kelly CRISPR & Gene Editing Technology ETF holds 133,661 shares of DTIL stock, representing 2.96% of its portfolio.

What is Matt Kane's approval rating as Precision BioSciences' CEO?

12 employees have rated Precision BioSciences Chief Executive Officer Matt Kane on Glassdoor.com. Matt Kane has an approval rating of 100% among the company's employees. This puts Matt Kane in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Precision BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Precision BioSciences investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), Alector (ALEC), Kaleido Biosciences (KLDO), Gossamer Bio (GOSS), Micron Technology (MU), Homology Medicines (FIXX), Heron Therapeutics (HRTX), Inovio Pharmaceuticals (INO) and Invitae (NVTA).

When did Precision BioSciences IPO?

(DTIL) raised $126 million in an initial public offering (IPO) on Thursday, March 28th 2019. The company issued 7,900,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Goldman Sachs, Jefferies and Barclays served as the underwriters for the IPO.

What is Precision BioSciences' stock symbol?

Precision BioSciences trades on the NASDAQ under the ticker symbol "DTIL."

How do I buy shares of Precision BioSciences?

Shares of DTIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Precision BioSciences' stock price today?

One share of DTIL stock can currently be purchased for approximately $0.36.

How much money does Precision BioSciences make?

Precision BioSciences (NASDAQ:DTIL) has a market capitalization of $40.98 million and generates $25.10 million in revenue each year. The company earns $-111,640,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis.

How many employees does Precision BioSciences have?

The company employs 192 workers across the globe.

How can I contact Precision BioSciences?

Precision BioSciences' mailing address is 302 EAST PETTIGREW STREET SUITE A-100, DURHAM NC, 27701. The official website for the company is www.precisionbiosciences.com. The company can be reached via phone at (919) 314-5512 or via email at jwong@bplifescience.com.

This page (NASDAQ:DTIL) was last updated on 9/29/2023 by MarketBeat.com Staff

My Account -